EGFR and non-small cell lung carcinoma: The expression of EGFR receptor in CTCs has been shown to be a predictive marker for non small cell lung cancer prognosis who are undergoing second-line therapy with AXD929 (EGFR tyrosine kinase inhibitor) [86].